CJC-1295 research guide for Deleni. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Deleni trying to locate CJC-1295, the foundational reality is that this compound is available only through an online research supply market. The key implication for Deleni researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. What follows is a practical research guide built specifically around CJC-1295, covering everything a Deleni researcher needs before placing a first order.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Deleni comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Assessing CJC-1295 vendors begins with the COA: request the batch-specific certificate before purchasing, not after. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are below the threshold for research use. Positive vendor signals beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Deleni
COA-verified · International tracking · Research grade
All use of CJC-1295 in Deleni or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Bacterial endotoxin contamination is the most serious safety risk specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
